{"doi":"10.1200/jco.23.02235","title":"Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279","abstract":"PURPOSE: To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS: were administered once per week throughout IMRT. Complete pathologic response (CPR) was the primary end point. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and adverse events were assessed with Common Terminology Criteria for Adverse Events v 4.0. RESULTS: Fifty-seven patients enrolled, of which 52 were evaluable. The median age was 58 years (range, 25-58), and 94% were White. Forty (77%) had stage II or III disease, and all had squamous histology. A median of six chemotherapy cycles (range, 1-8) were received. Eighty-five percent of RT plans were quality-reviewed with 100% compliance to protocol. Seven patients came off trial because of toxicity or patient withdrawal. Of 52 patients available for pathologic assessment, 38 (73% [90% CI, 61 to 83]) achieved CPR. No pelvic exenterations were performed. With a median follow-up of 51 months, the 12-month PFS was 74% (90% CI, 62.2 to 82.7) and the 24-month OS was 70% (90% CI, 57 to 79). The most common grade 3 or 4 adverse events were hematologic toxicity and radiation dermatitis. There was one grade 5 event unlikely related to treatment. CONCLUSION: Weekly C and G concurrent with IMRT sufficiently improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.","journal":"Journal of Clinical Oncology","year":2024,"id":425444,"datarank":0.6368878063816752,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.18752796534857658,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.18752796534857658,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":19,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9128,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01595061"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":256629,"name":"Wei Deng","orcid":"0000-0003-1778-2013","position":1,"is_corresponding":false},{"id":1223542,"name":"I. Peterson","orcid":null,"position":2,"is_corresponding":false},{"id":66134,"name":"Robert S. Mannel","orcid":null,"position":3,"is_corresponding":false},{"id":1175694,"name":"J. S. Thompson","orcid":"0000-0002-1045-1425","position":4,"is_corresponding":false},{"id":975220,"name":"Elizabeth Lokich","orcid":null,"position":5,"is_corresponding":false},{"id":1046131,"name":"Tashanna Myers","orcid":"0000-0002-4770-1408","position":6,"is_corresponding":false},{"id":1223543,"name":"P. Hanjani","orcid":null,"position":7,"is_corresponding":false},{"id":258149,"name":"David M. O’Malley","orcid":"0000-0002-2828-0177","position":8,"is_corresponding":false},{"id":1223096,"name":"Ki Y. Chung","orcid":"0000-0001-6586-2013","position":9,"is_corresponding":false},{"id":66131,"name":"David S. Miller","orcid":"0000-0002-8215-5887","position":10,"is_corresponding":false},{"id":457390,"name":"Frederick R. Ueland","orcid":"0000-0003-1213-7509","position":11,"is_corresponding":false},{"id":232377,"name":"Don S. Dizon","orcid":"0000-0001-6541-9580","position":12,"is_corresponding":false},{"id":259919,"name":"Austin Miller","orcid":"0000-0001-9739-8462","position":13,"is_corresponding":false},{"id":235192,"name":"Jyoti Mayadev","orcid":"0000-0003-4786-8192","position":14,"is_corresponding":false},{"id":280653,"name":"Charles A. Leath","orcid":"0000-0002-4034-6845","position":15,"is_corresponding":false},{"id":258132,"name":"Bradley J. Monk","orcid":"0000-0001-6985-0159","position":16,"is_corresponding":false},{"id":70177,"name":"Neil S. Horowitz","orcid":"0000-0002-4854-0642","position":0,"is_corresponding":true}],"reference_count":42,"raw_metadata":null,"created_at":"2026-07-19T01:58:26.927596Z","pmid":"38574312","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}